Drugs / CMAB809
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04049409 | Jun → Nov 2019 | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04049409 ↗ |
| Route | Intravenous | “CMAB809 will be administered by IV infusion” NCT04049409 ↗ |